Writer of the article:
Revealed Jul 23, 2024 • 4 minute learn
Article content material
Extra ACTG Displays Tackle Muscle Density and Space amongst Individuals Dwelling with HIV and COVID-19 Therapy
LOS ANGELES, July 23, 2024 (GLOBE NEWSWIRE) — ACTG, a worldwide medical trials community targeted on HIV and different infectious illnesses, will current an exploratory evaluation from the REPRIEVE trial demonstrating that former and present use of abacavir was related to the next incidence of main antagonistic cardiovascular occasions at AIDS 2024 in Munich, Germany. The oral presentation will happen on July 26, 2024, as a part of the session Comorbidities: The Coronary heart of the Matter, from 10:30-11:30 am CEST at Corridor B0b/Channel 5 and nearly.
Commercial 2
Article content material
“This rigorously constructed evaluation provides to the physique of proof that abacavir use is related to the next danger of cardiovascular occasions like coronary heart assaults and strokes,” mentioned ACTG Chair Judith Currier, M.D., M.Sc., College of California Los Angeles. “These information align with prior research that had been thought-about considerably controversial as a result of no precise mechanism was clearly demonstrated and must be taken into consideration by clinicians after they consider therapy choices for individuals residing with HIV.”
These are the newest findings from REPRIEVE, the primary large-scale medical trial to check a main prevention technique to cut back the elevated danger of heart problems amongst individuals residing with HIV. It discovered that members who took pitavastatin calcium (a each day statin tablet that lowers ldl cholesterol) decreased their danger of main antagonistic cardiovascular occasions by 36 % in contrast with these receiving a placebo over a median period of 5 years of comply with up.
The evaluation being offered at AIDS 2024 evaluated the function of prior and present use of choose antiretroviral remedies (together with abacavir, tenofovir, thymidine analogs, and protease inhibitors) on the event of main cardiovascular occasions. These antiretrovirals have been chosen primarily based upon prior affiliation with cardiovascular danger and kidney impairment (future analyses are deliberate to look at the function of different antiretrovirals). Amongst 7,769 members, 31.3 % have been born feminine and 65.2 % weren’t white. The median age was 50, LDL (low-density lipoprotein, a type of ldl cholesterol) was 108 mg/dL, CD4 depend was 621 cell/mm3, and 88 % had a viral load below 400 copies/mL. Contributors had been taking HIV therapy for a median of 9.5 years. Researchers discovered that present or previous use of abacavir elevated the danger of main antagonistic cardiovascular occasions by 42 and 50 %, respectively, whereas present or previous use of different antiretroviral remedies prompted no such improve.
High Tales
Article content material
Commercial 3
Article content material
“This evaluation is essential as we search to tease out the assorted components which will assist cut back cardiovascular danger in individuals residing with HIV,” mentioned lead research writer Carl Fichtenbaum, M.D., College of Cincinnati. “Whereas the affiliation between abacavir and cardiovascular danger is disappointing, it isn’t a shock. It’s, nonetheless, reassuring that the opposite HIV therapies included within the evaluation like tenofovir weren’t related to the next danger.”
REPRIEVE had numerous distinctive facets: research members had no recognized prior historical past of heart problems, the worldwide cohort from 12 international locations had low-to-moderate danger for heart problems, and all research endpoints have been independently vetted by the nationwide research Thrombolysis in Myocardial Infarction (TIMI).
REPRIEVE started in 2015 as cooperative agreements (HL12339, HL123336, HL164284, and HL164285) and was a collaborative effort between the Nationwide Institutes of Well being’s Nationwide Coronary heart, Lung, and Blood Institute (NHLBI) and the Nationwide Institute of Allergy and Infectious Illnesses (NIAID), two of the most important NIH institutes. It obtained extra funding from the NIH Workplace of AIDS Analysis, Kowa Prescription drugs America, Inc. (suppliers of pitavastatin calcium and placebo), Gilead Sciences, Inc., and ViiV HealthCare.
Commercial 4
Article content material
The trial is led by Steven Grinspoon, M.D. (Chair) and Pamela S. Douglas, M.D. (Co-chair), who led the Scientific Coordinating Heart and Heather Ribaudo, Ph.D. (Lead Statistician) and Michael Lu, M.D., M.P.H. (Protocol Chair, Mechanistic Substudy of REPRIEVE), who led the Information Coordinating Heart. To study extra, please go to www.reprievetrial.org.
Along with these information from REPRIEVE, ACTG may also make the next shows at AIDS 2024:
No Proof of Pitavastatin Impact on Muscle Density or Space Amongst Individuals with HIV (REPRIEVE; Poster Presentation: Tuesday, July twenty third, 12:00-1:00 pm CEST, Poster Exhibition Corridor) Kristine Erlandson, et al. This evaluation from the REPRIEVE mechanistic substudy discovered that statins didn’t cut back muscle density or space. This two-year research of middle-aged individuals residing with HIV at low-to-moderate danger of heart problems, confirmed by imaging that statins have been secure and didn’t trigger important muscle harm. That is reassuring to individuals who need to use statins to decrease their danger of cardiovascular occasions like coronary heart assaults and strokes.
Commercial 5
Article content material
Efficacy and Security of Ensitrelvir in Non-Hospitalized Adults at Normal or Excessive-Danger of Development to Extreme COVID-19: the SCORPIO-HR Section 3, Randomized, Double-Blind Placebo-Managed Trial (ACTG 5407; Poster Presentation: Tuesday, July twenty third, 12:00-1:00 pm CEST, Poster Exhibition Corridor) Kara Chew, et al. Whereas the oral protease inhibitor ensitrelvir demonstrated anti-viral exercise, security, and a development towards shorter time to symptom decision in comparison with placebo, SCORPIO-HR (ACTG 5407) didn’t meet its main endpoint of time to 2 or extra days sustained decision of 15 COVID-19 signs in outpatient members at commonplace and better danger for extreme illness.
About ACTG
ACTG is the world’s largest and longest working medical trials community targeted on HIV and different infectious illnesses and the individuals residing with them. It’s funded by NIAID and collaborating NIH Institutes below award numbers UM1 AI068636, UM1 AI107716, and UM1 AI068634. Based in 1987, ACTG conducts analysis to enhance the administration of HIV and its comorbidities; develop a remedy for HIV; and innovate remedies for tuberculosis, hepatitis B, and rising infectious illnesses. It includes 1000’s of devoted researchers, workers, and neighborhood members who’re pursuing analysis into novel remedies and cures for infectious illnesses at 65 places throughout 4 continents, with the last word purpose of advancing science that meaningfully impacts the lives of the individuals we serve.
Disclaimer: This content material is solely the accountability of ACTG and doesn’t essentially symbolize the official views of the NIH.
Media Contact:
Jenna Conley, ACTG
jenna@conleycommunications.internet
Article content material
